Hologic, Inc. (HOLX) continues to stir interest within the investment community due to a variety of reasons. Large investment firms like Bayesian Capital Management and Gotham Asset Management are increasing their positions in the bio-tech company, indicating confidence in its growth potential. As well, memberships from corporations like Crossmark Global Holdings and Orion Portfolio Solutions are taking contrasting actions, lowering their shares in Hologic. HOLX's projected regular earnings are expected to beat estimates which could prompt a stock price surge, as the estimates for Q3 2024 are hopeful. The company's recent
Q2 2024 earnings managed to beat estimates with entire fiscal year outlook raised. However, Hologic's HOLX Q1 earnings beat estimates but resulted in a lower gross margin. HOLX's stock performance, while occasionally underperforming relative to its competitors, regularly bounces back, displaying resilience. The announcement of Hologic's acquisition of Endomagnetics Ltd, a breast surgical guidance company, represents a significant developmental milestone. However, some insiders like Div. President, GYN Surgical Essex Mitchell have sold shares, potentially flagging concern. It's also important to note Hologic's
diagnostics division expects facility closures.
Hologic HOLX News Analytics from Thu, 12 Oct 2023 07:00:00 GMT to Sun, 16 Jun 2024 04:12:07 GMT -
Rating 6
- Innovation 5
- Information 8
- Rumor -4
